Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib

Video content above is prompted by the following questions:

• What are the primary differences in the toxicity profiles of abemaciclib and ribociclib when used in the adjuvant setting, and how are these prioritized when selecting a CDK4/6 inhibitor?
  • Discuss the recent publication of long-term patient-reported outcomes with adjuvant abemaciclib.